maker

WASHINGTON — The Supreme Court sided with the maker of the Roundup weedkiller Thursday in a ruling expected to block thousands of lawsuits alleging it failed to warn people the product could cause cancer.

The case came before the justices after a tidal wave of litigation that included some multibillion-dollar verdicts against the global agrochemical manufacturer Bayer, which acquired Roundup when it bought its original manufacturer Monsanto in 2018.

The decision is a victory for the Trump administration, but one that could be tricky politically since allies in the Make America Healthy Again movement want to rein in pesticide use.

The high court, in a 7-2 ruling, found that the company can’t be sued in state courts because federal regulations have found a cancer link unlikely and do not require a warning label.

The decision “is good for science, farmers, and industries that depend on regulatory clarity for innovation,” Bayer said in a statement. “It should help significantly contain the Roundup litigation after nearly a decade of legal battles.”

Though Bayer said the ruling should result in the dismissal of pending lawsuits containing failure-to-warn allegations, the company said it plans to proceed with a proposed $7.25 billion class-action settlement intended to resolve many of the remaining claims.

Lawyers for some residents pursuing Roundup litigation criticized the court’s decision.

“This Supreme Court ruling wrongly slams the courthouse door on Americans sickened by pesticides,” said attorney Christopher Seeger, who is proposed as a claimants’ representative in the settlement. But he said a settlement still would allow some people to receive compensation.

The case before the Supreme Court was filed by Missouri resident John Durnell. He developed a cancer called non-Hodgkin’s lymphoma after more than 20 years of serving as the neighborhood association’s “spray guy,” using Roundup on parks in his historic St. Louis community.

A jury agreed that the company failed to warn him about possible cancer dangers and awarded him $1.25 million. It’s one of thousands of similar cases, including some multibillion-dollar damage awards.

There’s still fierce debate about cancer and Roundup’s key ingredient, glyphosate. The World Health Organization’s International Agency for Research on Cancer classified the chemical as “probably carcinogenic” in 2015. The Environmental Protection Agency has determined that it’s not likely to cause cancer in humans when used as directed.

The agency approved a label without a cancer warning, and Bayer argues that it’s required to follow those federal standards — not the state laws that Durnell and others have sued under. The ruling still could allow other suits alleging problems with the way the product was designed, his attorney Ashley Keller has said.

Bayer disputes the cancer claims but previously set aside $16 billion to settle cases, and earlier this year proposed a $7.25 billion class-action settlement. A federal judge recently ruled that the proposed settlement will be heard in a Missouri state court, where many of the lawsuits have been filed. At the same time, the company has tried to persuade states to pass laws shielding it from liability in failure-to-warn lawsuits, and three states have agreed.

About 200,000 Roundup-related claims have been made against Bayer, mostly from home users. It has stopped using glyphosate in Roundup sold in the U.S. residential lawn and garden market.

The company has said it might have to consider pulling glyphosate from U.S. agricultural markets if it keeps getting sued. Agricultural industry group say could have a devastating effect on the food supply.

But pesticides have also created a rift between the Trump administration and members of Health Secretary Robert F. Kennedy’s MAHA movement, adding to their frustration with an executive order aimed at boosting glyphosate’s production.

Kennedy himself has said repeatedly that glyphosate causes cancer, even as he says he recognizes the executive order was necessary for food supply and national security reasons.

Whitehurst writes for the Associated Press. AP writer David A. Lieb in Jefferson City, Mo., contributed to this report.

SEOUL, June 25 (UPI) — South Korea’s industrial valve maker Komoto said Thursday that it is seeking to expand into the Kazakh market after wrapping up a field demonstration project in the Central Asian country.

The company said that it completed the installation and operational tests of its solar-powered smart flow control and SCADA system at a demonstration site in Kazakhstan.

Short for supervisory control and data acquisition, SCADA is an industrial automation system that enables operators to monitor, control, and collect real-time data from infrastructure remotely.

Following the successful trial, the system received final field performance certification from Kazvodkhoz, Kazakhstan’s state-owned water resources agency, according to Komoto.

The firm noted that the project confirmed the applicability of its technology to remote agricultural waterways and irrigation facilities not only in Kazakhstan but also across Central Asia.

Komoto CEO Ryan MK Ko said that the company plans to expand its presence in overseas water industry markets, particularly in Central Asia.

“Our biggest competitive edge is that our system allows for the stable operation of water management facilities even in remote areas with limited access to commercial power and communication infrastructure, while significantly reducing costs compared with conventional options,” Ko said in a statement.

“Based on the technology and operational data accumulated through pilot projects both at home and abroad, we will further advance our automated control and intelligent water management features,” he added.

Komoto is not publicly listed. It was founded in 1988 with technology and capital support from Motoyama, one of Japan’s leading manufacturers of industrial equipment, including valves.

Published on
22/06/2026 – 13:32 GMT+2

The German government announced on Monday that it intends to acquire 40% of the defence contractor KNDS, a move designed to bolster European arms production in partnership with its NATO and EU ally France.

ADVERTISEMENT

ADVERTISEMENT

The decision deepens state involvement in a company whose hardware has become central to Europe’s rearmament efforts.

KNDS was created in 2015 through the merger of Germany’s Krauss-Maffei Wegmann and France’s Nexter. The French state holds a 50% stake, while the other half belongs to the German family behind Krauss-Maffei Wegmann, whose planned exit has opened the door for Berlin to step in.

Based in Amsterdam, the group reported revenue of €4.4 billion last year and employs more than 11,000 people.

The timing reflects a broader scramble across Europe to expand military spending and manufacturing capacity, as governments weigh the continued threat from Russia’s war in Ukraine against growing doubts about the reliability of the US as a security guarantor.

Berlin framed the investment in explicitly strategic terms, saying it would secure lasting influence over a business it considers vital to European security and defence.

The German government added that the stake would reinforce domestic industrial output, technological independence and the safeguarding of key national security interests and technologies.

In a joint statement, Germany and France said they had agreed on the future strategy and governance of KNDS, which they intend to co-own through arrangements aimed at giving both countries equal shareholdings.

Clearing the path to a stock market listing

Neither government specified a timeline or the final level at which their holdings would settle, but they stated the agreement opens the way for a possible flotation of KNDS in the near future.

According to people familiar with the matter cited by the Associated Press, the two states plan to trim their stakes to around 30% within two to three years of any listing, while retaining equal voting rights regardless of the size of each holding.

The two governments cast the deal as a joint commitment to building up Europe’s defence industry and armed forces, and to securing the continent’s strategic independence well into the future.

State participation in the firm was first floated by German Defence Minister Boris Pistorius in 2025 as a way to protect strategic expertise and jobs.

Beyond its tanks, KNDS also manufactures the Puma infantry fighting vehicle and the Boxer and Dingo armoured personnel carriers, equipment which is in growing demand as European armies replenish stocks depleted by years of underinvestment and donations to Ukraine’s defence.

Additional sources • AP

PARIS — A founder of global gaming company Ubisoft, maker of “Assassin’s Creed,” was killed in a plane crash in western France, authorities said Saturday.

Claude Guillemot, co-founder of the company and president of the Guillemot Foundation, died in an accident, Ubisoft said in a statement to the Associated Press. It did not elaborate.

A Cessna plane carrying Guillemot and one other person crashed Friday evening in a field just before landing at La Baule Airport on the Atlantic coast, a La Baule airport official said. The official spoke on condition of anonymity because they were not authorized to be publicly named.

Local media said both people aboard were killed.

Guillemot and four brothers founded Ubisoft in 1986. In addition to the popular “Assassin’s Creed” franchise, Ubisoft’s games include “Just Dance,” and the “Rayman” and Tom Clancy game franchises.

Charlton writes for the Associated Press.

Published on
25/05/2026 – 10:57 GMT+2

Oura, the Finnish company that created the ring-shaped health tracker worn by millions worldwide, has confidentially submitted draft paperwork to the US Securities and Exchange Commission for a proposed IPO, according to several reports.

ADVERTISEMENT

ADVERTISEMENT

While the number of shares and the expected price range remain undisclosed, the company had a recent funding round in the fall of 2025 that valued the business at around $11 billion (€9.5bn), more than double the $5 billion (€4.3bn) valuation it earned in a previous round in 2024.

According to CEO Tom Hale, more than 5.5 million Oura rings had been sold up to the end of last year’s third quarter.

At the time, Hale also projected that the company would reach $2 billion (€1.7bn) in annual revenue in 2026 compared with $500 million (€430mn) just two years ago.

The move towards an IPO puts a European wearable brand on Wall Street’s radar at a time when investor appetite for consumer health technology appears to be returning.

Oura has become a standout name in the fast-growing smart ring category, competing against smartwatch giants such as Apple, Garmin and Samsung, while carving out a niche with a distinct piece of hardware that some consumers find less obtrusive.

Over the past two years, the company has expanded aggressively into software, subscriptions and AI-powered health analysis. Its wearable platform now focuses on long-term health signals including sleep, readiness, heart rate, stress and recovery.

More recently, Oura has pushed further into women’s health and AI-based personal coaching, including tools designed to interpret physiological data and provide tailored wellness recommendations.

Analysts see that transition from device maker to subscripton-based health platform as central to its IPO pitch as the firm is currently on pace to surpass 5 million paid members.

A European tech champion heading to US markets

The IPO filing marks a significant moment for one of Europe’s most prominent health tech success stories.

Founded in Finland and developed around research into sleep, recovery and biometric monitoring, Oura has grown from a Nordic hardware start-up into a global player in the wearable market.

However, for Europe’s start-up ecosystem, Oura’s planned listing carries broader significance.

While its roots and design philosophy are deeply tied to Finland, the company recently transitioned to a US-based parent company, named Oura Inc. and headquartered in San Francisco, to access American venture capital while keeping its European operations.

Its decision to prepare for a US listing rather than a European one reflects a wider pattern among high-growth European tech firms seeking deeper capital markets and greater visibility among global investors.

The planned flotation arrives during renewed debate over whether Europe is losing some of its most successful technology companies to US exchanges.

Oura joins a growing list of European-founded businesses choosing Wall Street as their route to public markets, drawn by scale, liquidity and stronger investor familiarity with consumer technology.

The company’s IPO will also be seen as a test of investor sentiment towards wearable technology after a mixed few years for the sector.

Unlike smartwatches, smart rings remain a relatively young category, though interest has accelerated rapidly.

Oura is widely viewed as the segment’s category leader and its public debut could offer a clearer benchmark for how markets value next-generation health hardware combined with software subscriptions and AI services.

May 2 (UPI) — A company that makes the abortion drug mifepristone on Saturday asked the U.S. Supreme Court to immediately pause a ruling that prevents doctors from prescribing it during telehealth visits.

Late Friday, a three judge panel on the 5th Circuit Court of Appeals unanimously ruled in favor of the state of Louisiana in a case asking the court to block doctors from prescribing the drug in telehealth visits.

Louisiana in the last four years has moved to prevent women in the state from obtaining abortion care legislators there were among the first to ban abortion after the repeal of Roe v. Wade, and later blocked doctors from prescribing the medical abortion pill in virtual telehealth visits.

The company, which is not the only drugmaker planning to file an appeal, said that patients will be stuck in limbo because of the lack of clarity it leaves for legal use of the drug, NBC News and Politico reported.

Roughly half of all abortions in the United States are performed using medications.

“Danco has been free to rely on procedures set by the FDA to distribute its product,” lawyers for the company said in a filing with the court.

“The Fifth Circuit’s decision immediately ends that,” the lawyers said. “A stay should issue to prevent the disruption and confusion that will result if the decision below were to remain operative.”

In addition to Danco, Politico reported that GenBioPro, which also manufactures the drug, has indicated that it will also file an appeal with the court.

Mifepristone was approved by the U.S. Food and Drug Administration in 2000 for medical termination of pregnancy and, until the COVID-19 pandemic, could only be prescribed during in-person appointments.

Early in the pandemic and the country locked down in an effort to stem the spread of the virus, doctors sued the FDA to allow them to prescribe mifepristone during telehealth visits.

The FDA temporarily changed the rule, but in 2023 adopted it permanently as some states started to restrict access to abortion and abortion services after the Supreme Court struck down Roe v. Wade.

Pharmaceutical companies and patient advocates warned that the restriction circumvents the FDA’s regulatory authority, which is based on evidence and data, and that it may offer a path for people to challenge other medications based on personal interest or opinion.

In the case of Danco, it also immediately filed the appeal because it is the only product it makes and “without a valid legal framework for distributing that product, Danco will lose its only source of revenue and may be unable to continue operating.”